A systematic review and Delphi study creates a new consensus statement on the meaning and measurement of relapse in ...
One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. A subcutaneous ...
A target trial emulation study finds no relapse reduction with cyclophosphamide added to glucocorticoids in eosinophilic ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Overall, people ...
The observational cohort study drew on data on 1620 patients (72.5% female; mean age, 55 years) from 38 referral centers in the French MS Registry. The study included 1452 patients in the HET ...
Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...
Patients ages 50 or older with non-active multiple sclerosis (MS) who discontinued high-efficacy therapy (HET) had a higher risk of relapse compared with those who continued HET, a matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback